Clinical reference Biomarker Directory
Back to directory

Pancreatic elastase-1

Established

Fecal elastase-1 is the modern preferred test for pancreatic exocrine insufficiency, replacing fecal chymotrypsin.

Also known as Fecal elastase-1 FE-1
In plain language

This enzyme test checks whether the pancreas is making enough digestive enzymes. It has replaced an older, similar test (chymotrypsin) because it stays more stable in stool samples and still works accurately even if a patient is already taking enzyme supplements.

Biomarker & context

Pancreatic elastase-1 is a digestive enzyme produced exclusively by the pancreas; fecal elastase-1 testing is the modern, preferred method for assessing pancreatic exocrine function.

What it indicates

Low fecal elastase-1 indicates pancreatic exocrine insufficiency, in which the pancreas fails to produce enough digestive enzymes, leading to malabsorption of fats and nutrients, seen in chronic pancreatitis, cystic fibrosis, and after pancreatic surgery.

Diagnosis & clinical testing

Measured via stool immunoassay; this test has become the modern replacement for fecal chymotrypsin testing, since it is more stable during intestinal transit and, importantly, is not affected by oral pancreatic enzyme replacement therapy, unlike chymotrypsin.

Guiding treatment

Confirmed pancreatic exocrine insufficiency is treated with pancreatic enzyme replacement therapy (PERT); because fecal elastase-1 isn't affected by PERT, it remains a reliable test even in patients already taking enzyme supplements, unlike the older chymotrypsin test.

Clinical significance

Remains accurate even in patients already taking pancreatic enzyme replacement therapy, unlike the older chymotrypsin test.

References
  1. General gastroenterology reference literature on fecal elastase-1 versus fecal chymotrypsin testing for pancreatic exocrine insufficiency.